Table 7.
Preoperative pharmacological analysis: type of drugs, indication for drug therapy, and time of drug exposure. ZOL: zoledronate; ALD: alendronate; PMT: pamidronate; COL: clodronate; DZM: denosumab; IBA: ibandronate; ETI: etidronate; mth: months; RSD: risedronate; NR: not reported.
| Study | Type of drug | Indication for drug therapy | time of drug exposure |
|---|---|---|---|
| Engroff and Kim (2007) [28] | PMT (x 1 case) ZOL (x 1 case) |
Brest Cancer (x 2 cases) | NR |
|
| |||
| Ferrari et al. (2008) [29] | PMT + ZOL | Multiple Myeloma | 21 mth (PMT) 3 mth (ZOL) discontinue therapy |
|
| |||
| Mücke et al. (2009) [30] | ZOL (x 2 cases) | Brest cancer (x 1 case); Multiple Myeloma (x 1 case) |
50mth (ZOL) 36 mth (ZOL) |
|
| |||
| Nocini et al. (2009) [31] | PMT and ZOL (x 5 cases) ZOL (x 2 cases) |
Brest Cancer (x 5 cases); Prostate Cancer (x 1 case); Myeloid leukaemia and Osteoporosis (x 1 case) |
NR |
|
| |||
| Seth et al. (2010) [32] | ZOL (x 6 cases) ALD (x 2 cases) IBA (x 2 cases) ETI (x 1 case) |
Brest Cancer (x 5 cases); Prostate Cancer (x 2 cases); Multiple Myeloma (x 2 cases); Osteoporosis (x 2 cases) |
NR |
|
| |||
| Bedogni et al. (2011) [33] | NR | NR | NR |
|
| |||
| Pautke et al. (2011) [34] | ZOL | Prostate Cancer | 40 mth |
|
| |||
| Bittner et al. (2012) [35] | ZOL and PMT | Pain syndrome | 12 mth (ZOL) 3 mth (PMT) |
|
| |||
| Ghazali et al. (2013) [36] | ALD | Osteoporosis | 84 mth (ALD) |
|
| |||
| Hanasono et al. (2013) [37] | ZOL (x 9 cases) PMT (x 2 cases) |
Multiple Myeloma (x 5 cases); Breast Cancer (x 2 cases); Prostate Cancer (x 2 cases); Osteoporosis (x 2 cases) |
NR |
|
| |||
| Horta et al. (2014) [38] | ZOL | Lung Cancer | 36 mth (ZOL) |
|
| |||
| Spinelli et al. (2014) [39] | ZOL (x 3 cases) PMT (x 3 cases) ZOL and PMT (x 2 cases) |
Multiple Myeloma (x 4 cases); Brest Cancer (x 3 cases); Prostate Cancer (x 1 case) |
1 x 27 mth (ZOL) 1 x 21 mth (ZOL) 1 x 35 mth (ZOL 1 x 22 mth (PMT) 1 x 30 mth (PMT) 1 x 19 mth (PMT 1 x 25 mth (ZOL and PMT) 1 x 17 mth (ZOL and PMT) |
|
| |||
| Vercruysse et al. (2014) [25] | 1 x ZOL 1 x ZOL + PMT 1 x ZOL + CLO |
Multiple Myeloma (x 2 case); Brest Cancer (x 1 case) |
1 x 22mth (ZOL) 1x 12 mth (PMT) + 26 mth (ZOL) 1x 96 mth (CLO) + 29mth (ZOL) |
|
| |||
| Kim et al. (2015) [40] | ALD (x 2) ALD + RSD + PMT (x 1) ZOL + PMT (x 1) |
Osteoporosis (x 3) Multiple Myeloma (x 1) |
1 x 48 mth (ALD) 1 x 120 mth (ALD 1 x 24 mth (ALD + RSD +PMT) 1 x 30mth (ZOL +PMT) |
|
| |||
| Mücke et al. (2016) [41] | NR | NR | NR |
|
| |||
| Neto et al. (2016) [26] | ZOL | Lung Cancer | 36 mth (ZOL) |
|
| |||
| Sotsuka et al (2016) [42] | ZOL | Brest Cancer | 59 mth (ZOL) |
|
| |||
| Caldroney et al. (2017) [43] | 7 x ZOL 2 x ALD 1 x ZOL + DZM 1 x PMT + DZM |
Brest Cancer (x 4 cases) Osteoporosi (x 3 cases) Multiple Myeloma (x 3 cases) Prostate Cancer (x 1 case) |
NR |